Pharmanovia in the news
Improving drugs for patients
Tamtam found 13 recent articles about Pharmanovia.
- IMPACT Therapeutics licenses Senaparib to Pharmanovia
IMPACT Therapeutics licensed exclusive rights for its drug senaparib to Pharmanovia for commercialization across 66 countries, focusing on ovarian cancer treatment.
- Eupraxia Pharma Partners with Pharmanovia to License Senaparib in 66 Countries Including EU; Shares Surge Over 12%
Eupraxia Pharma licensed its anti-cancer drug Senaparib to Pharmanovia for 66 countries, leading to a surge in Eupraxia Pharma's shares.
- Pharmanovia licenses China-approved PARP drug for up to €423.5M
Pharmanovia has licensed a China-approved PARP inhibitor drug for up to ․423.5M, expanding its oncology portfolio with a near-market ovarian cancer asset.
- IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib
Pharmanovia secured exclusive licensing rights from IMPACT Therapeutics for senaparib, a cancer treatment, across 66 countries for nearly $488 million.
- Pharmanovia Announces Launch of Korjuny (Catumaxomab) in Germany, a First-in-class Treatment for Malignant Ascites
Germany has introduced catumaxomab as the first approved drug therapy for malignant ascites to improve the quality of life for advanced cancer patients.
- Brothers’ little helper: why are investors losing faith in Pharmanovia?
Financial analysts and investors are questioning the strategic direction and stability of pharmaceutical company Pharmanovia.
- Fitch Downgrades Pharmanovia to 'CCC+'
Pharmanovia faced a credit rating downgrade to 'CCC+' following weak sales, high debt leverage, and significant management instability.
- Pharmanovia Seeks to Reassure Lenders as Performance Fears Grow
Pharmanovia is meeting with lenders to discuss turnaround plans and liquidity concerns following weak performance.
- Pharmanovia appoints Stephan Eder as CEO
Stephan Eder, a former STADA and Novartis executive with 20 years of industry experience, has taken over as CEO of Pharmanovia.
- Pharmanovia Appoints Stephan Eder as Chief Executive Officer
Stephan Eder, a former Stada and Sandoz executive, has taken over as the new CEO of Pharmanovia to lead its global expansion.
- Pharmanovia Selects Honeywell’s Trackwise Digital® to Accelerate Pharmaceutical Quality
Pharmanovia will implement Honeywell’s TrackWise Digital software to automate quality management and reduce manufacturing costs through cloud-based data analytics.
- PHARMANOVIA ACQUIRES GLOBAL CENTRAL NERVOUS SYSTEM (CNS) PORTFOLIO FROM SANOFI
Pharmanovia acquired 11 Central Nervous System brands from Sanofi, including Frisium® and Gardenal®, to expand its neurology portfolio and deepen its market presence.
- Stealth BioTherapeutics Enters into Exclusive Licensing Agreement with Pharmanovia to Commercialize Elamipretide for the Treatment of Barth Syndrome in Europe and Key Global Territories
A licensing agreement allows Pharmanovia to commercialize the investigational drug elamipretide for treating Barth syndrome across Europe and the MENA region.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Pharmanovia?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies